CONMED (NYSE:CNMD) Given New $120.00 Price Target at Stifel Nicolaus
CONMED (NYSE:CNMD – Free Report) had its target price lowered by Stifel Nicolaus from $136.00 to $120.00 in a research report released on Thursday morning, Benzinga reports. The firm currently has a buy rating on the stock. A number of other equities research analysts have also recently commented on the company. Piper Sandler raised their […]
More Stories
Western Asset High Yield Defined Opportunity Fund Inc. (NYSE:HYI) Declares Dividend of $0.10
Western Asset High Yield Defined Opportunity Fund Inc. (NYSE:HYI – Get Free Report) declared a dividend on Tuesday, November 19th,NASDAQ...
National Bank Financial Upgrades Choice Properties REIT (TSE:CHP) to “Hold”
Choice Properties REIT (TSE:CHP – Get Free Report) was upgraded by research analysts at National Bank Financial to a “hold”...
Banxa (CVE:BNXA) Stock Price Up 25.3% – Still a Buy?
Banxa Holdings Inc. (CVE:BNXA – Get Free Report)’s stock price was up 25.3% on Saturday . The company traded as...
Critical Survey: Establishment Labs (NASDAQ:ESTA) versus Bone Biologics (NASDAQ:BBLG)
Bone Biologics (NASDAQ:BBLG – Get Free Report) and Establishment Labs (NASDAQ:ESTA – Get Free Report) are both small-cap medical companies,...
Progyny (NASDAQ:PGNY) Stock Price Down 3% – Here’s Why
Shares of Progyny, Inc. (NASDAQ:PGNY – Get Free Report) were down 3% during mid-day trading on Thursday . The company...
Empresa Distribuidora y Comercializadora Norte Sociedad Anónima (NYSE:EDN) Trading Up 5.4% – Still a Buy?
Empresa Distribuidora y Comercializadora Norte Sociedad Anónima (NYSE:EDN – Get Free Report)’s stock price rose 5.4% on Thursday . The...